Article

The Importance of Clinical Trials in Multiple Myeloma

Author(s):

Dr. Sham Mailankody

As patients progress through therapy, it is important that oncologists not disregard the novel agents that are currently being investigated in clinical trials, according to Memorial Sloan Kettering Cancer Center’s Dr. Sham Mailankody.

The list of available treatment options for multiple myeloma has grown in the past decade, However, as patients progress through therapy, it is important that oncologists not disregard the novel agents that are currently being investigated in clinical trials, according to Memorial Sloan Kettering Cancer Center’s Dr. Sham Mailankody.

In an interview with OncLive®, CURE®’s sister publication, Mailankody explained how investigational drugs can play a role in the treatment of patients with myeloma as they advance past the initial lines of treatment.

Transcription:

I think with all these different treatment options, particularly in the relapsed/refractory setting, referring patients when appropriate to clinical trials of these novel treatments — for instance, the CAR-T cells and bispecific antibodies and others that are coming along that are not currently available as standard treatments but might provide significant clinical benefit for patients in the context of clinical trials — would be something else I think people should keep in mind as they see patients through their treatment course.

Related Videos
Image of a woman with tied back hair, wearing pearl earrings.
Image of a woman with layered hair, wearing a bright blue cardigan.
Image of a man with short black hair.
Image of man with gray hair.
Image of woman with black hair.
Image of a man wearing a black suit and tie.
Image of a man with white hair and a white goatee.
Image of a woman with brown wavy hair, wearing a navy blue top.
Image of a man wearing a suit with a red bowtie.
Related Content
Image of surgeons performing a surgery.
October 18th 2024

Danielle Fishel Undergoes Surgery for Breast Cancer, TikTok Star Dies of Rare Liver Cancer and More

Ashley Chan
From “Boy Meets World” actress Danielle Fishel discussing her breast cancer surgery to a young TikTok star dying from a rare liver cancer, here’s what’s happening in the cancer space this week.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Image of the FDA logo on a blue abstract background.
October 5th 2024

FDA Receives Application to Review D-VRd in Multiple Myeloma Subset

Darlene Dobkowski, MA
The biologics license application seeks potential approval of a Darzalex Faspro-based regimen for newly diagnosed multiple myeloma ineligible for transplant.
Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic
January 13th 2022

Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.
Illustration of cells.
September 23rd 2024

Outpatient CAR-T Cell Therapy May Be Safe in Hematologic Malignancies

Spencer Feldman
CAR-T cell therapies administered in an outpatient setting may be safe and feasible without intensive remote monitoring in hematologic malignancies.
FDA text.
September 20th 2024

FDA Approves Sarclisa In Newly Diagnosed Transplant-Ineligible Multiple Myeloma

Alex Biese
The Food and Drug Administration has approved Sarclisa as a first-line treatment for patients with multiple myeloma who are ineligible for autologous stem cell transplant.